{"id":"W4401942365","doi":"10.1182/blood.2024024582","title":"Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Pharmacyclics; Chugai Pharmaceutical; BeiGene; Regeneron Pharmaceuticals; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; National Cancer Research Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Hazard ratio; Internal medicine; Clinical endpoint; Progression-free survival; Confidence interval; Interim analysis; Multiple myeloma; Lenalidomide; Refractory (planetary science); Gastroenterology; Tolerability; Surgery; Randomized controlled trial; Adverse effect; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009422326,0.0005193888,0.001619468,0.0007330459,0.0001680181,0.001262151,0.0008765587,0.0005681143,0.00255084],"category_scores_gemma":[0.005224357,0.0002735563,0.003662095,0.0009860599,0.0002965686,0.0008043699,0.0006135271,0.00176446,0.0002977228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007687517,"about_ca_system_score_gemma":0.0005646734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001127827,"about_ca_topic_score_gemma":0.003723422,"domain_scores_codex":[0.9977246,0.001291717,0.0001848098,0.0002755481,0.0003794789,0.0001438257],"domain_scores_gemma":[0.9920483,0.004352593,0.002219619,0.0005334327,0.0004846196,0.0003613868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3894219,0.001613965,0.1417951,0.008979507,0.09366664,0.0002764733,0.0003108001,0.00654172,0.00944776,0.0007840918,0.01370706,0.333455],"study_design_scores_gemma":[0.08286056,0.04964337,0.7116963,0.0009786256,0.115493,0.0008949065,0.0001947619,0.004285788,0.004595606,0.001420332,0.02778015,0.0001566286],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8751785,0.09759285,0.0035741,0.001454409,0.0002790432,0.0007083488,0.01091708,0.0003341544,0.009961626],"genre_scores_gemma":[0.9806166,0.008920677,0.001316512,0.001068431,0.0003190037,0.0002568956,0.006417662,0.00006961414,0.001014719],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009422326,"threshold_uncertainty_score":0.04983068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04194345554366068,"score_gpt":0.3349759606370604,"score_spread":0.2930325050933997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}